Previous 10 | Next 10 |
On May 21, ANVS doubled on phase 2 data for improved cognition in Alzheimer's disease. The stock has increased more than 600% since my first coverage this January. Previously, ANVS reported ANVS-401 improved speed, coordination, motor function and significantly lowered inflammator...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The major stock market averages closed mixed for the week following a choppy day of trading Friday. The week saw the stock market bounced aro...
Annovis Bio (ANVS) intends to offer shares of its common stock in an underwritten public offering.Size and terms of the offering are yet to be finalized.Net proceeds to be primarily used for general corporate purposes, including working capital, research and development, capital exp...
Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that i...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Annovis Bio Inc. On the Rise After Releasing Alzheimer’s, Parkinson’s Study Results ” Annovis Bio Inc. (NASDAQ: ANVS) surged o...
Annovis Bio ([[ANVS]] +210.3%) has more than tripled in value in reaction to promising Phase 2 results for ANVS401, its lead asset for Alzheimer's disease ((AD)) and Parkinson's disease ((PD)).After 25 days of treatment, patients showed a statistically significant improvement of 4.4...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biopharmaceutical industry is seeing a big day from one of its players. Annovis Bio (NYSEMKT: ANVS ) stock is up huge with some big news. A drug trial is showing signs of significant improvement in subjects, and t...
Gainers: Annovis Bio (ANVS) +250%.Jiuzi Holdings (JZXN) +27%.Longeveron (LGVN) +25%.Wah Fu Education (WAFU) +22%.Mesa Royalty Trust (MTR) +20%.Gracell Biotechnologies (GRCL) +20%.Obalon Therapeutics (OBLN) +16%.Yalla Group (YALA) +16%.VOC Energy Trust (VOC) +12%.Cyclo Therapeut...
Annovis Bio (ANVS) announces promising results from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of Alzheimer's disease ((AD)) and Parkinson's disease ((PD)).Shares up more than 13% premarket.Patients treated with ANVS401 for 25...
Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced new results from a double-blind, placebo-co...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...